00:45 , Jun 5, 2019 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: May 2019

New Therapeutic Targets and Biomarkers: May 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during May. Therapeutic targets are defined as any protein, gene or other molecule...
17:52 , May 28, 2019 |  BC Innovations  |  Distillery Therapeutics

B. fragilis PSA for the prevention of Herpes simplex encephalitis

DISEASE CATEGORY: Infectious disease INDICATION: Encephalitis; herpes simplex virus (HSV) Mouse studies suggest B. fragilis PSA could help prevent encephalitis caused by HSV. In a mouse model of HSV encephalitis, pretreatment with B. fragilis PSA...
17:54 , Jan 9, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lymphoma; colorectal cancer Cell culture and mouse studies suggest an SAE1 inhibitor could help treat colorectal cancers, including those with high MYC expression. In vitro screening of a small molecule library, followed by optimization...
01:34 , Jun 22, 2018 |  BC Innovations  |  Targets & Mechanisms

T cell balancing act

Among the improvements to next-generation CAR T cell therapies is the need to optimize the ratios of the different T cell subsets. While CD8 + T cells have grabbed most of the attention, a study...
18:35 , Apr 3, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute lymphoblastic leukemia (ALL); B cell lymphoma; mantle cell lymphoma (MCL) Patient sample and mouse studies suggest inhibiting the pentose phosphate pathway with PP2A inhibitor LB-100, inhibition of G6PD or synergistic combination of both,...
16:43 , Aug 4, 2017 |  BC Week In Review  |  Financial News

Homology raises $83.5M series B

On Aug. 1, gene therapy company Homology Medicines Inc. (Lexington, Mass.) raised $83.5 million in a series B round led by Deerfield Management. Existing investors 5AM Ventures , Arch Venture Partners and Temasek also participated,...
22:53 , Aug 1, 2017 |  BC Extra  |  Financial News

Homology raises $83.5M in series B round

Gene therapy company Homology Medicines Inc. (Lexington, Mass.) raised $83.5 million in a series B round led by Deerfield Management. Existing investors 5AM Ventures , Arch Venture Partners and Temasek participated, as well as new...
20:03 , Apr 11, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Cell culture and mouse studies suggest inhibiting FTO or promoting METTL3 expression could help treat glioblastoma multiforme (GBM). In primary GBM stem cell-based assays of tumor formation, overexpression of METTL3 decreased growth...
20:03 , Apr 11, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Cell culture and mouse studies suggest inhibiting FTO or promoting METTL3 expression could help treat glioblastoma multiforme (GBM). In primary GBM stem cell-based assays of tumor formation, overexpression of METTL3 decreased growth...
07:00 , Aug 18, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Ubiquitin-like modifier activating enzyme 2 (UBA2; SAE2)

Cancer INDICATION: Colorectal cancer Patient sample and cell culture studies suggest inhibiting UBA2 could help treat colorectal cancer. In tissue samples from stage II and III colorectal cancer patients, tumor levels of UBA2 were higher...